Problem solving for tumor immunotherapy
- 1 May 2000
- journal article
- editorial
- Published by Springer Science and Business Media LLC in Nature Biotechnology
- Vol. 18 (5), 491-492
- https://doi.org/10.1038/75343
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanismNature Biotechnology, 2000
- TAP expression provides a general method for improving the recognition of malignant cells in vivoNature Biotechnology, 2000
- CpG-DNA Activates In Vivo T Cell Epitope Presenting Dendritic Cells to Trigger Protective Antiviral Cytotoxic T Cell ResponsesThe Journal of Immunology, 2000
- Regression of human metastatic renal cell carcinoma after vaccination with tumor cell–dendritic cell hybridsNature Medicine, 2000
- CpG DNA: A potent signal for growth, activation, and maturation of human dendritic cellsProceedings of the National Academy of Sciences, 1999
- A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cellNature, 1998
- MECHANISMS OF MHC CLASS I–RESTRICTED ANTIGEN PROCESSINGAnnual Review of Immunology, 1998
- CpG‐containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: A new class of vaccine adjuvantsEuropean Journal of Immunology, 1997